Searching for prognostic markers for Stage I epithelial ovarian cancer: A role for systemic inflammatory markers

Abstract

AbstractObjectiveTo determine the prognostic role of systemic inflammatory markers for Stage I epithelial ovarian cancer (EOC).Materials and MethodsWe performed a retrospective, single‐center, observational study. We included patients with Stage I EOC cancer undergoing primary surgery between 1993 and 2016. Inflammatory markers were assessed by analyzing blood samples collected at initial diagnosis before EOC surgery. We evaluated these markers' association with disease‐free survival (DFS) and cancer‐specific survival (CSS).ResultsWe included 176 women in our study. The neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), and systemic immune inflammation index (SII) were related to both DFS and CSS in the univariate analysis. In the multivariate Cox analysis, adjuvant chemotherapy (hazard ratio [HR] 0.17, 95% confidence interval [CI] 0.04–0.71, P = 0.02) and SII ≥730 (HR 6.84, 95% CI 1.30–35.9, P = 0.023) were independent predictors of DFS, while FIGO Stage IB–IC (HR 7.91, 95% CI 1.04–59.8, P = 0.04), NLR ≥3 (HR 56.8, 95% CI 7.46–433, P < 0.001) and PLR ≥169 (HR 49.1 95% CI 11.1–217.8, P = 0.005) were independent predictors of CSS.ConclusionsSystemic inflammatory markers are easily obtainable from patients' routine blood analyses and may represent inexpensive and reproducible prognostic markers in early‐stage EOC.